Intensity Therapeutics

Intensity Therapeutics Secures $2.35 Million in Public Offering to Advance Cancer Immunotherapy Trials

a month ago

• Intensity Therapeutics has priced a $2.35 million public offering to fund ongoing clinical trials of its novel intratumoral cancer therapy INT230-6, which has shown promise in killing tumors and triggering immune responses. • The offering includes 3.13 million shares of common stock with accompanying warrants at $0.75 per share, with proceeds primarily directed toward the INVINCIBLE-3 and INVINCIBLE-4 clinical studies targeting soft tissue sarcoma and triple-negative breast cancer. • INT230-6 represents a potentially paradigm-shifting approach to cancer treatment through direct intratumoral injection, having already demonstrated efficacy in clinical trials with over 200 patients across multiple cancer types.

Intensity Therapeutics' Novel Cancer Drug INT230-6 Shows Promise in Advanced Sarcoma and Breast Cancer

4 months ago

Intensity Therapeutics receives positive market outlook as Alliance Global Partners initiates coverage with a Buy rating, highlighting the potential of their lead compound INT230-6. The drug's dual mechanism of action targets tumor reduction while enhancing immune response in advanced soft tissue sarcoma and triple negative breast cancer patients.

Breyanzi Receives Positive CHMP Opinion for Follicular Lymphoma Treatment in EU

4 months ago

• The CHMP has recommended Breyanzi for treating relapsed or refractory follicular lymphoma (FL) in adults after two or more prior systemic therapies. • The recommendation is based on the Phase 2 TRANSCEND FL study, which showed a 97.1% overall response rate and a 94.2% complete response rate. • Breyanzi demonstrated rapid and durable responses, with 75.7% of patients in response at 18 months, and a consistent safety profile in clinical trials. • The European Commission will review the CHMP recommendation, with a final decision expected within approximately two months.

Intensity Therapeutics' Sarcoma Trial INT230-6 Authorized to Continue by DMC

4 months ago

• Intensity Therapeutics' Phase 3 INVINCIBLE-3 study of INT230-6 in soft tissue sarcoma is authorized to continue without modifications after a Data Monitoring Committee review. • The global, randomized trial compares intratumoral INT230-6 to standard-of-care chemotherapy in patients with leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. • INT230-6 showed a median overall survival of 21.3 months in Phase 1/2 data, compared to 6.7 months in a synthetic control, alongside increased T-cell activation and a favorable safety profile. • The INVINCIBLE-3 study is actively recruiting across the US, Canada, and Europe, aiming to enroll 333 patients to evaluate overall survival and safety.

Intensity Therapeutics' INT230-6 Shows Promise in Localized Cancer Reduction and Systemic Immune Activation

6 months ago

• Intensity Therapeutics is pioneering localized cancer reduction with INT230-6, designed to kill tumors and stimulate the immune system. • Clinical trials of INT230-6 have shown promising results in metastatic cancers and locally advanced breast cancer, with ongoing Phase 3 studies. • The company's DfuseRxSM platform addresses challenges of intratumoral drug delivery by creating drugs miscible in dense, fatty tumors. • INT230-6 aims to improve patient outcomes by debulking tumors and generating a systemic immune response, potentially extending survival.

Intensity Therapeutics Secures $3 Million to Advance Cancer Therapies

6 months ago

• Intensity Therapeutics has secured $3 million through a direct stock offering and private placement to bolster its working capital. • The funds will support ongoing clinical trials, including a Phase 3 trial for soft tissue sarcoma and a Phase 2/3 program for triple-negative breast cancer. • The company's innovative intratumoral injection technology aims to promote cell death and adaptive immune responses in tumors. • Recent Phase 1/2 trial results showed improved survival rates and a favorable safety profile for INT230-6 in treating various sarcomas.

Windtree and Intensity Therapeutics Report Progress in Heart Failure and Oncology

6 months ago

• Windtree Therapeutics reported positive Phase 2b results for istaroxime in early cardiogenic shock, showing significant improvements in cardiac function and blood pressure. • Intensity Therapeutics initiated a Phase 3 trial for INT230-6 in soft tissue sarcoma and a Phase 2 trial in triple-negative breast cancer. • Both companies provided financial updates, highlighting research and development expenses and cash runway into 2025.

Intensity Therapeutics and Fractyl Health Advance Clinical Programs in Oncology and Metabolic Disease

6 months ago

• Intensity Therapeutics doses first patient in Phase 2 trial for triple-negative breast cancer and progresses Phase 3 sarcoma study. • Fractyl Health reports progress in Revita and Rejuva platforms, with key data readouts expected in late 2024 and 2025. • Fractyl Health's REMAIN-1 study is evaluating Revita's efficacy in maintaining weight loss after GLP-1 therapy discontinuation. • Both companies highlight financial results, with Intensity focusing on INT230-6 development and Fractyl on Revita and Rejuva.

Intensity Therapeutics and SAKK Initiate Phase 2 Trial of INT230-6 in Triple-Negative Breast Cancer

7 months ago

• Intensity Therapeutics and SAKK collaborate on INVINCIBLE-4, a Phase 2 trial evaluating INT230-6 plus standard-of-care (SOC) versus SOC alone in localized triple-negative breast cancer (TNBC). • The primary endpoint of the study is to assess the pathological complete response (pCR) rate in the primary tumor and affected lymph nodes. • INT230-6, combines cisplatin and vinblastine with a penetration enhancer, aims to induce tumor cell necrosis and stimulate an anti-cancer immune response. • The randomized, open-label, multicenter study plans to enroll approximately 54 patients in Switzerland and France.